Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy

1. A heterocyclic compound of the formula (I)

wherein

A is

R is R 1 —W-A 1 -Q-Y-A 2 -X 1 —, wherein —Y-A 2 -X 1 — comprises at least atoms in the main chain;

R 1 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 12 -cycloalkyl-C 1 -C 4 -alkyl, halogenated C 1 -C 6 -alkyl, hydroxy -C 1 -C 4 alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, amino-C 1 -C 4 -alkyl, C 1 -C 6 -alkylamino-C 1 -C 4 -alkyl, di-C 1 -C 6 -alkylamino-C 1 -C 4 -alkyl, C 1 -C 6 -alkyloxycarbonylamino-C 1 -C 4 -alkyl, C 1 -C 6 -alkylaminocarbonylamino-C 1 -C 4 -alkyl, C 1 C 6 alkylsulfonylamino-C 1 -C 4 -alkyl, optionally substituted C 6 -C 12 -aryl-C 1 -C 4 -alkyl, optionally substituted C 3 -C 12 -heterocyclyl-C 1 -C 4 -alkyl, C 3 -C 12 -cycloalkyl, aminocarbonyl, C 1 -C 6 -alkylaminocarbonyl, C 2 -C 6 -alkenyl, optionally substituted C 6 -C 12 aryl, hydroxy, C 1 -C 6 -alkylamino, (halogenated C 1 -C 6 -alkyl)amino, di-C 1 -C 6 -alkylamino, di-(halogenated C 1 -C 6 -alkyl)amino, C 1 -C 6 -alkylcarbonylamino, (halogenated C 1 -C 6 alkyl)carbonylamino, C 6 -C 12 -arylcarbonylamino, C 1 -C 6 -alkylsulfonylamino, (halogenated C 1 -C 6 -alkyl)sulfonylamino, C 6 -C 1 -arylsulfonylamino or optionally substituted C 3 -C 12 -heterocyclyl;

W is —NR 8 — or a bond;

A 1 is optionally substituted C 1 -C 4 -alkylene or a bond;

Q is —S(O) 2 —, —C(O)— or a bond;

Y is —NR 9 —or a bond;

A 2 is optionally substituted C 1 -C 4 -alkylene, C 1 -C 4 -alkylene-CO—, —CO—C 1 -C 4 -alkylene, C 1 -C 4 -alkylene-O—C 1 -C 4 -alkylene, C 1 -C 4 -alkylene-NR 10 —C 1 -C 4 -alkylene, optionally substituted C 2 -C 4 -alkenylen, optionally substituted C 2 -C 4 -alkynylene, optionally substituted C 6 -C 12 -arylene, optionally substituted C 6 -C 1 -heteroarylene or a bond;

X 1 is —O—, —NR 11 —, —S—, optionally substituted C 1 -C 4 -alkylene, optionally substituted C 2 -C 4 -alkenylen, optionally substituted C 2 -C 4 -alkynylene or a bond,

with the proviso that if Q is a bond, W is —NR 8 — or Y is —NR 9 —;

R 2 is hydrogen, halogen, C 1 -C 6 -alkyl, halogenated C 1 -C 4 -alkyl, hydroxy-C 1 -C 4 -alkyl, —CN, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, optionally substituted C 6 -C 12 -aryl, hydroxy, C 1 -C 6 -alkoxy, halogenated C 1 -C 6 -alkoxy, C 1 -C 6 -alkoxycarbonyl, C 2 -C 6 -alkenyloxy, C 6 -C 12 -aryl-C 1 -C 4 -alkoxy, C 1 -C 6 -alkylcarbonyloxy, C 1 -C 6 -alkylthio, C 1 -C 6 -alkylsulfinyl, C 1 -C 6 -alkylsulfonyl, aminosulfonyl, amino, C 1 -C 6 -alkylamino, C 2 -C 6 -alkenylamino, nitro or optionally substituted C 3 -C 12 -heterocyclyl, or two radicals R 2 together with the ring atoms of A to which they are bound form an optionally substituted 5-or 6-membered ring;

R 3 is hydrogen, halogen, C 1 -C 6 -alkyl or C 1 -C 6 -alkoxy, or two radicals R 3 together with the carbon atom to which they are attached form a carbonyl group;

R 4 is hydrogen, C 1 -C 6 -alkyl, halogenated C 1 -C 4 -alkyl, hydroxy-C 1 -C 4 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, amino-C 1 -C 4 -alkyl, CH 2 CN, —CHO, C 1 -C 4 -alkylcarbonyl, (halogenated C 1 -C 4 -alkyl)carbonyl, C 1 -C 4 -alkoxycarbonyl, C 6 -C 12 -arylcarbonyl, C 1 -C 6 -alkylaminocarbonyl, C 2 -C 6 -alkenyl, —C(═NH)NH 2 , —C(═NH)NHCN, C 1 -C 6 -alkylsulfonyl, C 6 -C 12 -arylsulfonyl, amino or C 3 -C 12 -heterocyclyl;

X 2 is —O—, —NR 6 —, —S—, >CR 12a R 12b or a bond;

X 3 is —O—, —NR 7 —, —S—, >CR 13a R 13b or a bond;

R 5 is optionally substituted C 6 -C 12 -aryl, optionally substituted C 3 -C 12 -cycloalkyl or optionally substituted C 3 -C 12 -heterocyclyl;

n is 0, 1, or 2;

R 6 is hydrogen or C 1 -C 6 -alkyl;

R 7 is hydrogen or C 1 -C 6 -alkyl;

R 8 is hydrogen or C 1 -C 6 -alkyl;

R 9 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 12 -cycloalkyl, amino-C 1 -C 6 -alkyl, optionally substituted C 6 -C 12 -aryl-C 1 -C 4 -alkyl or C 3 -C 12 -heterocyclyl; or

R 9 , R 1

together are C 1 -C 4 -alkylene; or

R 9 is C 1 -C 4 -alkylene that is bound to a carbon atom in A 2 and A 2 is C 1 -C 4 -alkylene or to a carbon atom in X 1 and X 1 is C 1 -C 4 -alkylene;

R 10 is hydrogen, C 1 -C 6 -alkyl or C 1 -C 6 -alkylsulfonyl;

R 11 is hydrogen or C 1 -C 6 -alkyl, or

R 9 , R 11

together are C 1 -C 4 -alkylene,

R 12a is hydrogen, optionally substituted C 1 -C 6 -alkyl, C 1 -C 6 -alkylamino-C 1 -C 4 -alkyl, di-C 1 -C 6 -alkylamino-C 1 -C 4 -alkyl, C 3 -C 12 -heterocyclyl-C 1 -C 6 -alkyl, optionally substituted C 6 -C 12 -aryl or hydroxy;

R 12b is hydrogen or C 1 -C 6 -alkyl, or

R 12a , R 12b

together are carbonyl or optionally substituted C 1 -C 4 -alkylene, wherein one —CH 2 — of C 1 -C 4 -alkylene may be replaced by an oxygen atom or —NR 14 —;

R 13a a is hydrogen, optionally substituted C 1 -C 6 -alkyl, C 1 -C 6 -alkylamino-C 1 -C 4 -alkyl, di-C 1 -C 6 -alkylamino-C 1 C 4 -alkyl, C 3 -C 12 -heterocyclyl-C 1 -C 6 -alkyl, optionally substituted C 6 -C 12 -aryl or hydroxy;

R 13b is hydrogen or C 1 -C 6 -alkyl, or

R 13a , R 13b

together are carbonyl or optionally substituted C 1 -C 4 -alkylene, wherein one —CH 2 — of C 1 -C 4 -alkylene may be replaced by an oxygen atom or —NR 15 —;

R 14 is hydrogen or C 1 -C 6 -alkyl;

R 15 is hydrogen or C 1 -C 6 -alkyl; and

or a physiologically tolerated salt thereof.

2. The compound or physiologically tolerated salt thereof of claim 1 , wherein R 1 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 12 -cycloalkyl-C 1 -C 4 -alkyl, halogenated C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, amino-C 1 -C 4 -alkyl, C 1 -C 6 -alkylamino-C 1 -C 4 -alkyl, di-C 1 -C 6 -alkylamino-C 1 -C 4 -alkyl, C 1 -C 6 -alkyloxycarbonylamino-C 1 -C 4 -alkyl, C 1 -C 6 -alkylaminocarbonylamino-C 1 -C 4 -alkyl, C 6 -C 12 -aryl-C 1 -C 4 -alkyl, C 3 -C 12 -cycloalkyl, C 2 -C 6 -alkenyl, optionally substituted C 6 -C 12 -aryl, hydroxy, C 1 -C 6 -alkylamino, (halogenated C 1 -C 6 -alkyl)amino, di-C 1 -C 6 -alkylamino or optionally substituted C 3 -C 12 -heterocyclyl.

3. The compound or physiologically tolerated salt thereof of claim 1 , wherein A 1 is a bond, or A 1 is C 1 -C 4 alkylene and W is —NR 8 —.

4. The compound or physiologically tolerated salt thereof of claim 1 , wherein A 2 is optionally substituted C 1 -C 4 -alkylene, or A 2 is C 6 -C 12 -arylene selected from the group consisting of phen-1,4-ylene and phen-1,3-ylene, or C 6 -C 12 -heteroarylene selected from the group consisting of pyrid-2,5-ylene and pyrid-2,4-ylene.

5. The compound or physiologically tolerated salt thereof of claim 1 , wherein X 1 is —O— or —NR 11 , or X 1 is optionally substituted C 1 -C 4 -alkylene and A 2 is a bond, or X 1 is a bond.

6. The compound or physiologically tolerated salt thereof of claim 1 , wherein —Y-A 2 -X 1 — is —NR 9 —C 1 -C 4 -alkylene-.

7. The compound or physiologically tolerated salt thereof of claim 1 , wherein R 1 —W-A 1 -Q-Y-A 2 -X 1 — is R 1 —S(O) 2 —NH-A 2 -X 1 —, R 1 NH—S(O) 2 -A 2 -X 1 —, R 1 —C(O)—NH-A 2 -X 1 —, R 1 —NH—C(O)-A 2 -X 1 — or R 1 —NH-A 2 -X 1 —.

8. The compound or physiologically tolerated salt thereof of claim 1 , having one of the formulae

wherein R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4 , X 2 , X 3 , R 5 , n are as defined in claim 1 .

9. The compound or physiologically tolerated salt thereof of claim 1 , wherein R 4 is hydrogen, C 1 -C 6 -alkyl, halogenated C 1 -C 4 -alkyl, amino-C 1 -C 4 -alkyl, CH 2 CN, C 1 -C 4 -alkylcarbonyl, (halogenated C 1 -C 4 -alkyl)carbonyl, C 1 -C 4 alkoxycarbonyl, —C(═NH)NH 2 , —C(═NH)NHCN, C 1 -C 6 -alkylsulfonyl, amino or C 3 -C 12 -heterocyclyl.

10. The compound or physiologically tolerated salt thereof of claim 1 , wherein X 2 is >CR 12a R 12b , and X 3 is a bond.

11. The compound or physiologically tolerated salt thereof of claim 1 , wherein R 12a is hydrogen and R 12b is hydrogen, or R 12a is C 1 -C 6 -alkyl and R 12b is hydrogen or C 1 -C 6 -alkyl, or R 12a , R 12b together are optionally substituted C 1 -C 4 -alkylene.

12. The compound or physiologically tolerated salt thereof of claim 1 , wherein R 5 is optionally substituted aryl.

13. The compound or physiologically tolerated salt thereof of claim 12 , having the formula

wherein A, R, R 2 , R 3 , R 4 , X 2 , X 3 , n are as defined in claim 1 ; and

R 15a , R 15b , R 15c , R 15d , R 15e , R 15f

independently are hydrogen, halogen, optionally substituted C 1 -C 6 -alkyl, halogenated C 1 -C 6 -alkyl, CN, hydroxy, C 1 -C 6 -alkoxy, amino, C 1 -C 6 -alkylamino, di-C 1 -C 6 -alkylamino or C 3 -C 12 -heterocyclyl.

14. The compound or physiologically tolerated salt thereof of claim 13 , wherein R 9 is hydrogen.

15. The compound or physiologically tolerated salt thereof of claim 14 , wherein n is 1.

16. The compound or physiologically tolerated salt thereof of claim 1 , wherein

A is a ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:

R is R 1 —W-A 1 -Q-Y-A 2 -X 1 —, wherein —Y-A 2 -X 1 — comprises at least 2 atoms in the main chain;

R 1 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 12 -cycloalkyl-C 1 -C 4 -alkyl, halogenated C 1 -C 6 -alkyl, C 3 -C 12 -cycloalkyl, optionally substituted C 6 -C 12 -aryl, or optionally substituted C 3 -C 12 -heterocyclyl;

W is a bond;

A 1 is a bond;

Q is —S(O) 2 —, —C(O)— or a bond;

Y is —NR 9 — or a bond;

with the proviso that if Q is a bond, Y is —NR 9 —;

A 2 is C 1 -C 4 -alkylene;

X 1 is a bond;

R 2 is hydrogen;

R 3 is hydrogen;

R 4 is hydrogen or C 1 -C 4 -alkoxycarbonyl;

X 2 is >CR 12a R 12b ;

X 3 is a bond;

R 5 is optionally substituted phenyl;

R 9 is hydrogen or C 3 -C 12 -heterocyclyl; and

R 12a is hydrogen;

R 12b is hydrogen, or

R 12a , R 12b

together are optionally substituted C 1 -C 4 -alkylene.

17. A pharmaceutical composition comprising a carrier and the compound of claim 1 .

18. A method for treating a neurologic or psychiatric disorder or pain in a mammalian patient in need thereof comprising administering to the patient a therapeutically effective amount of the compound or physiologically tolerated salt thereof of claim 1 , wherein the neurologic or psychiatric disorder is selected from the group consisting of: glycinergic neurotransmission dysfunction, glutamatergic neurotransmission dysfunction, dementia, cognitive impairment, attention deficit disorder, hyperactivity, anxiety disorder, depression, a bipolar disorder, schizophrenia, and a psychotic disorder.

19. The compound or physiologically tolerated salt thereof of claim 1 , selected from the group consisting of:

7-(1-Phenylcyclobutyl)-2-(2-(propylsulfonamido)ethyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine;

N-(Azetidin-3-yl)-N-(2-(7-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)propane-1-sulfonamide;

(8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methanamine;

2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethanamine;

2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethanamine;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)propane-1-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)-1-methyl-1H-pyrazole-4-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)-3-fluoropropane-1-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)-1-methyl-1H-imidazole-4-sulfonamide;

N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)propane-1-sulfonamide;

N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-1-cyclopropylmethanesulfonamide;

N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-1-methyl-1H-pyrazole-4-sulfonamide;

N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-1-methyl-1H-imidazole-4-sulfonamide;

N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-3-fluoropropane-1-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)propane-1-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)ethanesulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)methanesulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)benzenesulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)butane-1-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-1-methyl-1H-pyrazole-4-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-1-methyl-1 H-imidazole-4-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-3-fluoropropane-1-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)cyclobutanesulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-1-cyclopropylmethanesulfonamide;

N-(2-(7-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-2-methylpropane-1-sulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)pyridine-3-sulfonamide;

N-(2-(7-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-N-methylpropane-1-sulfonamide;

N-(2-{1-[1-(4-Chlorophenyl)cyclobutyl]-1,2,3,4-tetrahydro-9H-b-carbolin-9-yl}ethyl)propane-1-sulfonamide;

N-(2-(4-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)propane- 1-sulfonamide;

N-(2-(4-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl- 1H-pyrazole-4-sulfonamide;

N-(2-(4-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl- 1H-imidazole-4-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)propane-1-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl) propyl)propane-1-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)-1-methyl- 1H -pyrazole-4-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl) propyl)-1-methyl- 1H -imidazole-4-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)methanesulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)ethanesulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)ethanesulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)methanesulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)butane-1-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-cyclopropylmethanesulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-2-methylpropane-1-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)cyclobutanesulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)propane-2-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)benzenesulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl-1H-pyrazole-4-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl-1H-imidazole-4-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)pyridine-2-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)pyridine-3-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)pyridine-4-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)butane-1-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)-2-methylpropane-1-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)-1-cyclopropylmethanesulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)cyclobutanesulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)propane-2-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)benzenesulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)pyridine-2-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)pyridine-3-sulfonamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)pyridine-4-sulfonamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl-1H-imidazole-4-carboxamide;

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl-1H-pyrazole-4-carboxamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)-1-methyl-1H-pyrazole-4-carboxamide;

N-(3-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)propyl)-1-methyl-1H-imidazole-4-carboxamide; and

N-(2-(4-(4-chlorobenzyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl-1H-pyrazole-4-carboxamide.